Dianthus Therapeutics (Nasdaq: DNTH) announced the initiation of the EMERGE Phase 3 trial evaluating claseprubart in generalized Myasthenia Gravis (gMG) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE